Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of pembrolizumab plus carboplatin/taxane induction followed by pembrolizumab with or without MK-2870 maintenance in first-line metastatic squamous non-small cell lung cancer
MOH_2024-05-26_013429Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sacituzumab tirumotecan, pembrolizumab, carboplatin and paclitaxel in Pulmonary squamous cell carcinoma (2 arms), sponsored by Merck & Co. Primary endpoint: Overall survival. Started May 2024; status: recruiting.
02
Drugs
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on MOH_2024-05-26_013429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-26_013429.